AGIO Agios Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 30, 2026
$31.80
· % 处于52周区间
· 高于低点
· 至高点
$22.2452周低点
$46.0052周高点
市值 (MRQ)
$1.90B
P/E (TTM)
-4.5
EPS (TTM)
$-7.02
收入 (TTM)
$98M
AGIO 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$31.80
市值 (MRQ)
$1.90B
P/E (TTM)
-4.5
EPS (TTM)
$-7.02
收入 (TTM)
$98M
ROE (TTM)
-34.3%
52周区间
$22–$46
AGIO 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 Agios Pharmaceuticals, Inc. - Common Stock 公司概况（来自维基百科）
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.
In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration.
In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.
In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency.
Corporate governance
As of August 2022, Agios' CEO is Brian Goff.
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工539
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$54M2016-12-31 → 2025-12-31
EPS$-7.122019-12-31 → 2025-12-31
自由现金流$-377M2016-12-31 → 2025-12-31
净利率-418.2%2017-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | AGIO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -4.55年均值 ≈-2.0 | ≈-2.0 | · | · | |
| P/S (TTM) | 19.35年均值 ≈59.0 | ≈59.0 | 25.9 | 公允价值 | |
| 市净率 (MRQ) | 1.85年均值 ≈1.4 | ≈1.4 | 6.0 | 低估 | |
| 股价/自由现金流 (TTM) | -5.25年均值 ≈-4.5 | ≈-4.5 | · | · | |
| 市现率 (TTM) | -5.35年均值 ≈-4.5 | ≈-4.5 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 2013.95年均值 ≈1.4 | ≈1.4 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | AGIO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -466.8%5年均值 ≈-1558.0% | ≈-1558.0% | -474.4% | 顶尖 | |
| EBITDA Margin (息税折旧摊销前利润率) | -873.9%5年均值 ≈-1558.0% | ≈-1558.0% | -474.4% | 顶尖 | |
| Pretax Margin (税前利润率) | -765.9%5年均值 ≈-434.8% | ≈-434.8% | -660.8% | 弱 | |
| 净利润率 (TTM) | -418.2%5年均值 ≈-464.6% | ≈-464.6% | -442.9% | 顶尖 | |
| ROA (TTM) | -31.9%5年均值 ≈22.9% | ≈22.9% | -34.8% | 顶尖 | |
| ROE (TTM) | -34.3%5年均值 ≈13.4% | ≈13.4% | -76.5% | 顶尖 | |
| ROIC | -39.5% | · | -134.2% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | AGIO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 10.25年均值 ≈13.3 | ≈13.3 | 7.7 | 流动性强 | |
| Quick Ratio (速动比率) | 1.15年均值 ≈1.8 | ≈1.8 | 4.3 | 低流动性 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | AGIO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 48.0%5年均值 ≈57.5% | ≈57.5% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 56.0% | · | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率（3年）) | -24.0% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | -25.1% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | AGIO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.05年均值 ≈0.0 | ≈0.0 | 0.3 | 弱 | |
| Inventory Turnover (库存周转率) | 0.25年均值 ≈0.2 | ≈0.2 | · | · | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$100.2K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
5.5%
下次报告
十月 28, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 七月 29, 2026 | $-1.69 | $-1.70 | 0.66% |
| 2026年3月31日 | $-1.69 | $-1.84 | 8.0% | |
| 2025年12月31日 | $-1.86 | $-1.99 | 6.3% | |
| 2025年9月30日 | $-1.78 | $-1.94 | 8.1% | |
| 2025年6月30日 | $-1.93 | $-1.84 | -4.7% | |
| 2025年3月31日 | $-1.55 | $-1.82 | 14.8% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Cost of Revenue | $6M | $4M | $3M | $2M | $0 | $0 | $1M | $1M | $0 | $0 | · | · | |
| R&D Expense | $340M | $301M | $296M | $280M | $257M | $221M | $214M | $341M | $293M | $220M | $142M | $100M | |
| SG&A Expense | $180M | $157M | $120M | $122M | $121M | $115M | $102M | $114M | $71M | $51M | $36M | $19M | |
| Operating Expenses | $526M | $462M | $418M | $403M | $378M | $336M | $316M | $457M | $364M | $271M | $178M | $119M | |
| Operating Income | $-472M | $-426M | $-391M | $-389M | $-378M | $-336M | $-316M | $-362M | $-321M | $-201M | $-119M | $-54M | |
| Interest Income | · | · | · | $13M | $836.0K | $7M | $15M | $16M | $6M | $3M | $968.0K | $203.0K | |
| Other Non-op | $2M | $6M | $6M | $7M | $14M | $0 | $0 | · | · | · | · | · | |
| Pretax Income | $-414M | $718M | $-352M | $-232M | $-357M | $-329M | $-301M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Income Tax | $-1M | $44M | $0 | $0 | · | · | $0 | $0 | $0 | $0 | $0 | $-426.0K | |
| Net Income | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| Shares (Basic) | 57,972,004 | 56,807,415 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| Shares (Diluted) | 57,972,004 | 57,889,255 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| EBITDA | $-472M | $-426M | $-391M | $-389M | $-378M | $-316M | $-418M | $-362M | $-321M | $-201M | $-119M | $-54M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $89M | $76M | $88M | $139M | $203M | $127M | $81M | $71M | $103M | $161M | $72M | $14M | |
| Short-term Investments | · | · | · | · | · | · | · | $515M | $321M | $381M | · | · | |
| Inventory | $33M | $28M | $19M | $8M | $0 | $15M | $7M | $869.0K | $0 | · | · | · | |
| Prepaid Expense | $44M | $40M | $35M | $39M | $40M | $16M | $24M | $17M | $18M | $10M | $9M | $5M | |
| Current Assets | $942M | $966M | $834M | $833M | $1.06B | $637M | $612M | $614M | $445M | $560M | $337M | $360M | |
| PP&E (Net) | $11M | $12M | $15M | $23M | $29M | $31M | $31M | $24M | $24M | $25M | $23M | $6M | |
| PP&E (Gross) | $71M | $68M | $68M | $73M | $74M | $72M | $64M | $50M | $44M | $39M | $31M | $12M | |
| Accum. Depreciation | $60M | $56M | $52M | $50M | $45M | $41M | $32M | $26M | $19M | $13M | $8M | $6M | |
| Other Non-current Assets | $4M | $5M | $4M | $4M | $3M | $0 | $0 | $238.0K | $891.0K | $2M | $611.0K | $590.0K | |
| Total Assets | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Accounts Payable | $18M | $17M | $10M | $19M | $17M | $18M | $22M | $18M | $23M | $17M | $15M | $11M | |
| Accrued Liabilities | $45M | $47M | $43M | $30M | $32M | $31M | $53M | $42M | $34M | $32M | $16M | $14M | |
| Current Liabilities | $82M | $81M | $68M | $63M | $60M | $94M | $93M | $94M | $95M | $88M | $53M | $61M | |
| Capital Leases | $22M | $40M | $57M | $72M | $86M | $97M | $106M | · | · | · | · | · | |
| Other Non-current Liabilities | $90.0K | $880.0K | $1M | $3M | $0 | · | · | · | · | · | · | · | |
| Total Liabilities | $104M | $122M | $126M | $138M | $146M | $453M | $250M | $171M | $239M | $261M | · | · | |
| Common Stock | · | · | · | · | $71.0K | $69.0K | $68.0K | $58.0K | $49.0K | $42.0K | $38.0K | $37.0K | |
| Retained Earnings | $-562M | $-149M | $-823M | $-471M | $-239M | $-1.84B | $-1.52B | $-1.10B | $-798M | $-483M | $-285M | $-167M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $0 | · | · | · | · | · | · | |
| Stockholders' Equity | $1.19B | $1.54B | $811M | $1.10B | $1.29B | $400M | $641M | $688M | $376M | $359M | $345M | $424M | |
| Liabilities + Equity | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Shares Outstanding | 58,448,592 | 73,372,696,000 | 72,161,489 | 71,256,118 | 70,550,631 | 69,293,920 | 68,401,105 | 58,218,653 | 48,826,153 | 42,220,444 | 37,696,502 | 37,100,513 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $8M | $7M | $6M | · | · | · | |
| Stock-based Comp | $53M | $43M | $45M | $49M | $54M | $62M | $58M | $73M | $48M | $42M | $32M | $12M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | · | · | · | $-40M | · | · | · | · | · | |
| Operating Cash Flow | $-373M | $-390M | $-296M | $-309M | $-407M | $-291M | $-371M | $-304M | $-285M | $39M | $-77M | $-59M | |
| CapEx | $4M | $2M | $999.0K | $5M | $6M | $14M | $12M | $7M | $5M | $10M | $20M | $2M | |
| Investing Cash Flow | $377M | $363M | $240M | $243M | $1.25B | $76M | $91M | $-274M | $-58M | $-119M | $128M | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | $0 | $334M | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | · | $334M | |
| Financing Cash Flow | $9M | $14M | $5M | $2M | $-766M | $262M | $290M | $546M | $285M | $170M | $6M | · | |
| Net Change in Cash | $13M | $-12M | $-51M | $-64M | $76M | $47M | $10M | $-32M | $-58M | $89M | $58M | $-58M | |
| Taxes Paid | $628.0K | $43M | $2M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-377M | $-392M | $-297M | $-314M | $-413M | $-306M | $-383M | $-311M | $-290M | $29M | $-97M | $-62M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -361.6% | · | -745.8% | · | · | -82.8% | |
| Net Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | · | -161.1% | -349.0% | · | -731.6% | · | · | -81.9% | |
| Pretax Margin | -765.9% | 1967.2% | -1312.6% | -1627.8% | · | -161.2% | -349.0% | · | -731.6% | · | · | -82.5% | |
| EBITDA Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -354.7% | · | -745.8% | · | · | -82.8% | |
| ROA | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% | -25.8% | -15.4% | |
| ROE | -32.2% | 42.5% | -41.5% | -21.6% | 119.4% | -74.4% | -75.6% | -47.8% | -85.7% | -56.4% | -30.6% | -19.2% | |
| ROIC | -39.5% | -25.9% | · | · | · | · | -66.6% | -52.7% | -85.4% | · | · | -12.7% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 | 6.7 | 6.6 | 6.6 | 4.7 | 6.3 | 6.4 | 5.9 | |
| Quick Ratio | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 | 1.4 | 0.9 | 6.3 | 4.5 | 1.8 | 1.4 | 0.2 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.2 | 0.1 | · | 0.1 | · | · | 0.2 | |
| Inventory Turnover | 0.2 | 0.2 | 0.2 | 0.4 | · | 0.3 | 0.3 | 3.2 | · | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.41 | $26.96 | $14.50 | $20.00 | $23.78 | $5.77 | $9.36 | $11.81 | $7.69 | $8.49 | $9.16 | $11.44 | |
| Revenue / Share | $0.93 | $0.63 | $0.48 | $0.26 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-6.43 | $-6.73 | $-5.32 | $-5.65 | $-6.74 | · | · | · | · | · | · | · | |
| Cash / Share | $1.52 | $1.33 | $1.58 | $2.53 | $3.74 | $1.84 | $1.18 | $1.21 | $2.10 | $3.81 | $1.90 | $0.38 | |
| EPS (TTM) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | $-1.59 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 48.0% | 36.1% | 88.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 56.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -24.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -25.1% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Net Income TTM | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Market Cap | $1.59B | $1.88B | $1.25B | $1.55B | $1.79B | $3.00B | $3.27B | $2.68B | $2.79B | $1.76B | $2.45B | $4.16B | |
| P/E | -3.8 | 2.8 | -3.5 | -6.6 | 1.2 | -9.1 | -7.0 | · | · | · | · | -70.5 | |
| P/S | 29.4 | 51.5 | 46.4 | 108.5 | · | · | 27.7 | 28.4 | 64.9 | 25.2 | 41.4 | 63.6 | |
| P/B | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | 5.1 | 3.9 | 7.4 | 4.9 | 7.1 | 9.8 | |
| P / Tangible Book | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.3 | -4.8 | -4.2 | -5.0 | -4.4 | -10.3 | -8.8 | -8.8 | -9.8 | 45.7 | -31.8 | -70.0 | |
| P / FCF | -4.2 | -4.8 | -4.2 | -4.9 | -4.3 | -9.8 | -8.5 | -8.6 | -9.6 | 61.5 | -25.2 | -67.5 | |
| Earnings Yield | -26.2% | 35.4% | -28.4% | -15.1% | 80.8% | -10.9% | -14.4% | · | · | · | · | -1.4% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $21M | $20M | $13M | $12M | $9M | $11M | $9M | $9M | $8M | $7M | $7M | $7M | $6M | $4M | $4M | |
| Cost of Revenue | $3M | $1M | $2M | $2M | $2M | $1M | $1M | $783.0K | $1M | $627.0K | $586.0K | $633.0K | $1M | $554.0K | $413.0K | $517.0K | |
| R&D Expense | $101M | $81M | $88M | $87M | $92M | $73M | $83M | $72M | $77M | $69M | $77M | $82M | $69M | $67M | $70M | $65M | |
| SG&A Expense | $52M | $48M | $52M | $41M | $46M | $42M | $52M | $39M | $36M | $31M | $35M | $26M | $30M | $28M | $33M | $29M | |
| Operating Expenses | $155M | $131M | $142M | $130M | $140M | $115M | $136M | $112M | $114M | $100M | $113M | $108M | $100M | $96M | $103M | $95M | |
| Operating Income | $-111M | $-110M | $-122M | $-117M | $-127M | $-107M | $-125M | $-103M | $-106M | $-92M | $-106M | $-101M | $-94M | $-91M | $-99M | $-91M | |
| Other Non-op | $119.0K | $119.0K | $113.0K | $67.0K | $523.0K | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $1M | $1M | |
| Pretax Income | · | · | $-109M | $-103M | · | · | $-105M | $1.00B | · | · | $-96M | $-91M | · | · | · | · | |
| Income Tax | · | · | $-1M | $0 | · | · | $-9M | $53M | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Income | $-101M | $-99M | $-108M | $-103M | $-112M | $-89M | $-97M | $948M | $-96M | $-82M | $-96M | $-91M | $-84M | $-81M | $37M | $-82M | |
| EPS (Basic) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.65 | $16.65 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| EPS (Diluted) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.44 | $16.22 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| Shares (Basic) | 59,488,871 | 58,782,241 | · | 58,139,277 | 57,932,576 | 57,459,195 | · | 56,939,403 | 56,802,546 | 56,383,475 | · | 55,803,663 | 55,604,330 | 55,265,390 | · | 54,844,579 | |
| Shares (Diluted) | 59,488,871 | 58,782,241 | · | 58,139,277 | 57,932,576 | 57,459,195 | · | 58,432,796 | 56,802,546 | 56,383,475 | · | 55,803,663 | 55,604,330 | 55,265,390 | · | 54,844,579 | |
| EBITDA | $-111M | $-110M | · | $-117M | $-127M | $-107M | · | $-103M | $-106M | $-92M | · | $-101M | $-94M | $-91M | · | $-91M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $100M | $114M | $89M | $93M | $81M | $79M | $76M | $254M | $85M | $119M | · | $64M | $85M | $104M | · | $122M | |
| Inventory | $36M | $35M | $33M | $32M | $31M | $30M | $28M | $26M | $24M | $23M | · | $17M | $16M | $11M | · | $5M | |
| Prepaid Expense | $46M | $47M | $44M | $43M | $45M | $42M | $40M | $40M | $35M | $39M | · | $38M | $37M | $39M | · | $46M | |
| Current Assets | $718M | $835M | $942M | $1.03B | $1.02B | $969M | $966M | $1.07B | $632M | $664M | · | $704M | $757M | $792M | · | $785M | |
| PP&E (Net) | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | $13M | $14M | · | $17M | $20M | $21M | · | $25M | |
| PP&E (Gross) | · | · | $71M | · | · | · | $68M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $60M | · | · | · | $56M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $10M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $4M | · | $4M | $4M | $4M | · | $4M | |
| Total Assets | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Accounts Payable | $16M | $14M | $18M | $20M | $18M | $14M | $17M | $17M | $10M | $11M | · | $13M | $12M | $9M | · | $10M | |
| Accrued Liabilities | $35M | $26M | $45M | $37M | $35M | $21M | $47M | $33M | $37M | $25M | · | $30M | $29M | $22M | · | $30M | |
| Current Liabilities | $70M | $59M | $82M | $75M | $70M | $52M | $81M | $119M | $63M | $52M | · | $58M | $55M | $45M | · | $54M | |
| Capital Leases | $12M | $17M | $22M | $27M | $31M | $36M | $40M | $45M | $49M | $53M | · | $61M | $65M | $68M | · | $75M | |
| Other Non-current Liabilities | $240.0K | $90.0K | $90.0K | $90.0K | $101.0K | $880.0K | $880.0K | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $82M | $76M | $104M | $101M | $102M | $89M | $122M | $165M | $113M | $106M | · | $120M | $121M | $115M | · | $130M | |
| Retained Earnings | $-762M | $-661M | $-562M | $-454M | $-350M | $-238M | $-149M | $-52M | $-1.00B | $-904M | · | $-727M | $-635M | $-552M | · | $-507M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | · | $802M | $802M | $802M | · | $802M | |
| Stockholders' Equity | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B | $1.63B | $661M | $744M | $811M | $887M | $964M | $1.04B | $1.10B | $1.05B | |
| Liabilities + Equity | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Shares Outstanding | 59,604,830 | 59,341,338 | 58,448,592 | 58,279,876 | 58,038,545 | 57,886,781 | 57,156,285 | 57,021,543 | 56,875,079 | 56,751,511 | 72,161,489 | 55,883,973 | 55,734,775 | 55,541,367 | 71,256,118 | 54,894,031 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $16M | $16M | $14M | $12M | $15M | $11M | $11M | $11M | $12M | $9M | $14M | $9M | $12M | $10M | $11M | $11M | |
| Operating Cash Flow | $-57M | $-119M | $-96M | $-88M | $-77M | $-111M | $-133M | $-84M | $-73M | $-100M | $-72M | $-62M | $-67M | $-95M | $-66M | $-71M | |
| CapEx | $1M | $769.0K | $1M | $2M | $875.0K | $766.0K | $967.0K | $419.0K | $158.0K | $141.0K | $234.0K | $369.0K | $-3.0K | $399.0K | $113.0K | $38.0K | |
| Investing Cash Flow | $40M | $141M | $90M | $96M | $79M | $113M | $-49M | $251M | $37M | $125M | $96M | $39M | $47M | $58M | $83M | $104M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Financing Cash Flow | $3M | $2M | $3M | $4M | $65.0K | $2M | $5M | $3M | $1M | $6M | $847.0K | $2M | $237.0K | $2M | $22.0K | $1M | |
| Net Change in Cash | $-14M | $24M | $-4M | $12M | $2M | $3M | $-177M | $169M | $-34M | $31M | $24M | $-20M | $-19M | $-35M | $17M | $34M | |
| Taxes Paid | $70.0K | $4.0K | $-940.0K | $65.0K | $1M | $188.0K | $44M | $-34.0K | $-78.0K | $-525.0K | $-17.0K | $785.0K | $801.0K | $0 | · | $98.0K | |
| Free Cash Flow | · | $-120M | · | · | · | $-112M | · | · | · | $-100M | · | · | · | $-96M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| Net Margin | -225.1% | -477.7% | · | -803.0% | -899.4% | -1023.2% | · | 10574.7% | -1115.7% | -995.8% | · | -1234.3% | -1248.6% | -1444.4% | · | -2325.0% | |
| Pretax Margin | · | · | · | -803.0% | · | · | · | 11167.3% | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| ROA | -7.8% | -7.2% | · | -6.5% | -10.0% | -7.4% | · | 67.7% | -10.3% | -8.2% | · | -8.3% | -7.2% | -6.5% | · | -6.0% | |
| ROE | -8.4% | -7.7% | · | -7.1% | -11.0% | -8.1% | · | 75.4% | -11.8% | -9.2% | · | -9.4% | -8.0% | -7.2% | · | -6.7% | |
| ROIC | · | · | · | -9.1% | · | · | · | -6.0% | · | · | · | · | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.2 | 14.2 | · | 13.8 | 14.5 | 18.5 | · | 9.0 | 10.1 | 12.8 | · | 12.1 | 13.7 | 17.5 | · | 14.6 | |
| Quick Ratio | 1.4 | 1.9 | · | 1.2 | 1.1 | 1.5 | · | 2.1 | 1.3 | 2.3 | · | 1.1 | 1.5 | 2.3 | · | 2.3 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $17.21 | $18.69 | · | $22.04 | $23.60 | $25.33 | · | $28.53 | $11.61 | $13.11 | · | $15.87 | $17.30 | $18.66 | · | $19.13 | |
| Revenue / Share | $0.75 | $0.35 | · | $0.22 | $0.21 | $0.15 | · | $0.15 | $0.15 | $0.15 | · | $0.13 | $0.12 | $0.10 | · | $0.06 | |
| Cash Flow / Share | · | $-2.02 | · | · | · | $-1.94 | · | · | · | $-1.77 | · | · | · | $-1.72 | · | · | |
| Cash / Share | $1.67 | $1.91 | · | $1.59 | $1.39 | $1.36 | · | $4.45 | $1.49 | $2.09 | · | $1.15 | $1.52 | $1.88 | · | $2.23 | |
| EPS (TTM) | $-7.02 | $-7.26 | · | $-6.70 | $11.30 | $11.54 | · | $11.37 | $-6.49 | $-6.31 | · | $-3.94 | $-3.79 | $-3.96 | · | $-2.34 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $66M | · | $45M | $41M | $37M | · | $33M | $31M | $29M | · | $24M | $20M | $19M | · | $10M | |
| Net Income TTM | $-411M | $-423M | · | $-401M | $650M | $666M | · | $674M | $-365M | $-353M | · | $-220M | $-210M | $-218M | · | $-363M | |
| Market Cap | $2.21B | $2.01B | · | $2.34B | $1.93B | $1.70B | · | $2.53B | $2.45B | $1.66B | · | $1.38B | $1.58B | $1.28B | · | $1.55B | |
| P/E | -5.3 | -4.7 | · | -6.0 | 2.9 | 2.5 | · | 3.9 | -6.6 | -4.6 | · | -6.3 | -7.5 | -5.8 | · | -12.1 | |
| P/S | 22.5 | 30.4 | · | 52.2 | 47.2 | 45.8 | · | 77.1 | 78.3 | 56.4 | · | 57.6 | 78.3 | 67.1 | · | 156.3 | |
| P/B | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Tangible Book | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Cash Flow | · | -16.9 | · | · | · | -15.2 | · | · | · | -16.6 | · | · | · | -13.4 | · | · | |
| Earnings Yield | -18.9% | -21.5% | · | -16.7% | 34.0% | 39.4% | · | 25.6% | -15.0% | -21.6% | · | -15.9% | -13.4% | -17.2% | · | -8.3% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $54M | $36M | $27M | $14M | $0 |
| 营业利润率 % | -873.9% | -1166.5% | -1459.5% | -2732.1% | · |
| 净收入 | $-413M | $674M | $-352M | $-232M | $1.60B |
| 稀释后每股收益 (EPS) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 |
| 速动比率 | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-377M | $-392M | $-297M | $-314M | $-413M |
机构持有人 (13F) 262 家申报者 · $2.7B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
262
持有价值
$2.7B
新仓位
39
已退出持仓
30
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 39 (-2 与上一季度对比) | 30 (-2 与上一季度对比) | 96 (+16 与上一季度对比) | 69 (-19 与上一季度对比) | +8.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $239582050 | 6455997 | 8.88% | 股份 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $219594714 | 5917400 | 8.14% | 股份 |
| VANGUARD GROUP INC | $152278288 | 5594353 | 5.64% | 股份 |
| STATE STREET CORP | $131144972 | 3533633 | 4.86% | 股份 |
| Lynx1 Capital Management LP | $126505652 | 3408937 | 4.69% | 股份 |
| D. E. Shaw & Co., Inc. | $115300956 | 3107005 | 4.27% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $107552091 | 2898197 | 3.98% | 股份 |
| ARMISTICE CAPITAL, LLC | $104279100 | 2810000 | 3.86% | 买入期权 |
| VANGUARD CAPITAL MANAGEMENT LLC | $99523268 | 2681845 | 3.69% | 股份 |
| ARMISTICE CAPITAL, LLC | $89064000 | 2400000 | 3.30% | 股份 |
| Erste Asset Management GmbH | $81972396 | 2154900 | 3.04% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $78332000 | 2110809 | 2.90% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $58433490 | 1574268 | 2.17% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $51046957 | 1375558 | 1.89% | 股份 |
| ADAR1 Capital Management, LLC | $47799647 | 1288053 | 1.77% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47502433 | 1280044 | 1.76% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $46345467 | 1248738 | 1.72% | 股份 |
| GOLDMAN SACHS GROUP INC | $42711087 | 1150932 | 1.58% | 股份 |
| UBS Group AG | $36584189 | 985831 | 1.36% | 股份 |
| MORGAN STANLEY | $35746487 | 963256 | 1.32% | 股份 |
| Nuveen, LLC | $32417811 | 873560 | 1.20% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $30078768 | 810530 | 1.11% | 股份 |
| Foresite Capital Management VI LLC | $29131350 | 785000 | 1.08% | 股份 |
| CITADEL ADVISORS LLC | $27190015 | 732687 | 1.01% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $25395858 | 684340 | 0.94% | 股份 |
| Parkman Healthcare Partners LLC | $24828297 | 669046 | 0.92% | 股份 |
| SCS Capital Management LLC | $22742864 | 612850 | 0.84% | 股份 |
| Qube Research & Technologies Ltd | $22178346 | 597638 | 0.82% | 股份 |
| NORTHERN TRUST CORP | $20585250 | 554709 | 0.76% | 股份 |
| Defilade Capital Management, L.P. | $20293529 | 546848 | 0.75% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19969930 | 538128 | 0.74% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $19905062 | 536380 | 0.74% | 股份 |
| Rock Springs Capital Management LP | $19763413 | 532563 | 0.73% | 股份 |
| Schonfeld Strategic Advisors LLC | $19300279 | 520083 | 0.72% | 股份 |
| BANK OF AMERICA CORP /DE/ | $18847034 | 507869 | 0.70% | 股份 |
| Point72 Asset Management, L.P. | $18790426 | 506344 | 0.70% | 股份 |
| JANE STREET GROUP, LLC | $18280312 | 492598 | 0.68% | 股份 |
| Legal & General Group Plc | $16132422 | 434719 | 0.60% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $14690661 | 395868 | 0.54% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $13876579 | 373931 | 0.51% | 股份 |
| KENNEDY CAPITAL MANAGEMENT LLC | $13850565 | 373230 | 0.51% | 股份 |
| JPMORGAN CHASE & CO | $13783528 | 359756 | 0.51% | 股份 |
| Connor, Clark & Lunn Investment Management Ltd. | $13342901 | 359550 | 0.49% | 股份 |
| Squarepoint Ops LLC | $11917431 | 321138 | 0.44% | 股份 |
| Ensign Peak Advisors, Inc | $11045049 | 297630 | 0.41% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $9996803 | 269383 | 0.37% | 股份 |
| ALGERT GLOBAL LLC | $9203540 | 248007 | 0.34% | 股份 |
| JANE STREET GROUP, LLC | $7974939 | 214900 | 0.30% | 卖出期权 |
| Palo Alto Investors LP | $7926733 | 213601 | 0.29% | 股份 |
| Tetragon Partners GP Ltd | $7629037 | 205579 | 0.28% | 股份 |
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION, CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC | 2021年4月5日 | · | 初始申报 | · | SEC |
| CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 申报 | 2019年11月14日 | · | 初始申报 | 资本结构 | SEC |
| CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 申报 | 2014年12月17日 | · | 初始申报 | 资本结构 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 38 位内幕人士 · 18 位高管 · 20 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Brian Goff | Chief Executive Officer | 2026年6月18日 A | 184508 | 0 | 7 | $-1691387 |
| Cecilia Jones | Chief Financial Officer | 2026年6月18日 A | 54998 | 0 | 6 | $-334266 |
| Jonathan Biller | Chief Financial Officer | 2022年3月1日 A | 22953 | 0 | 0 | $0 |
| Andrew Hirsch | Chief Financial Officer | 2020年4月22日 M | 24272 | 0 | 0 | $0 |
| John Duncan Higgons | Chief Operating Officer | 2016年1月4日 M | 120834 | 0 | 0 | $0 |
| Sarah Gheuens | Chief Medical Officer | 2026年8月4日 S | 54645 | 0 | 10 | $-1625034 |
| Krishnan Viswanadhan | Chief Strategy and Operations | 2026年6月18日 A | 10282 | 0 | 2 | $-184967 |
| Tsveta Milanova | Chief Commercial Officer | 2026年6月18日 A | 46829 | 0 | 5 | $-353311 |
| James William Burns | Chief Legal Officer | 2026年6月18日 A | 49306 | 0 | 6 | $-344391 |
| Theodore James Washburn Jr. | Principal Accounting Officer | 2026年3月3日 S | 868 | 0 | 4 | $-216633 |
| Richa Poddar | Chief Commercial Officer | 2022年10月15日 M | 8508 | 0 | 0 | $0 |
| Bruce Car | Chief Scientific Officer | 2022年3月1日 A | 16752 | 0 | 0 | $0 |
| Carman Alenson | Principal Accounting Officer | 2021年6月21日 M | 0 | 0 | 0 | $0 |
| Christopher Bowden | Chief Medical Officer | 2021年6月18日 M | 15487 | 0 | 0 | $0 |
| Darrin Miles | Chief Commercial Officer | 2021年5月14日 S | 7209 | 0 | 0 | $0 |
| Scott Biller | Chief Scientific Officer | 2019年6月11日 M | 33729 | 0 | 0 | $0 |
| Steven L. Hoerter | Chief Commercial Officer | 2019年3月4日 M | 10941 | 0 | 0 | $0 |
| Glenn Goddard | Senior Vice President, Finance | 2016年2月16日 A | 0 | 0 | 0 | $0 |
| Jay T. Backstrom | 董事 | 2026年7月8日 M | 1447 | 0 | 0 | $0 |
| Adams Catherine Owen | 董事 | 2026年6月18日 A | 10865 | 0 | 0 | $0 |
| Rahul D. Ballal | 董事 | 2026年6月18日 A | 15230 | 0 | 0 | $0 |
| David Scadden | 董事 | 2026年6月18日 A | 20419 | 0 | 2 | $-16968 |
| Maykin Ho | 董事 | 2026年6月18日 A | 19848 | 0 | 0 | $0 |
| Cynthia Smith | 董事 | 2026年6月18日 A | 15230 | 0 | 0 | $0 |
| Jacqualyn A Fouse | 董事 | 2026年6月18日 A | 154156 | 0 | 0 | $0 |
| Kaye I Foster-Cheek | 董事 | 2026年6月18日 A | 10284 | 0 | 0 | $0 |
| Jeffrey D Capello | 董事 | 2026年6月18日 A | 10865 | 0 | 0 | $0 |
| David P Schenkein | 董事 | 2024年6月20日 A | 126242 | 0 | 0 | $0 |
| Paul J Clancy | 董事 | 2022年6月21日 A | 6549 | 0 | 0 | $0 |
| John Maraganore | 董事 | 2022年6月21日 A | 30028 | 0 | 0 | $0 |
| Ian T Clark | 董事 | 2022年5月20日 M | 6549 | 0 | 0 | $0 |
| Lewis Clayton Cantley Jr. | 董事 | 2017年12月7日 S | 79515 | 0 | 0 | $0 |
| Robert Nelsen | 董事 | 2017年3月6日 S | 0 | 0 | 0 | $0 |
| Douglas G. Cole | 董事 | 2016年8月10日 J | 2778 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | 董事 | 2016年6月21日 A | 101009 | 0 | 0 | $0 |
| Perry A Karsen | 董事 | 2015年6月23日 A | · | 0 | 0 | $0 |
| Kevin P Starr | 董事 | 2015年2月19日 J | 184386 | 0 | 0 | $0 |
| Celgene European Investment Co LLC | 10% 所有者 | 2014年12月16日 P | 1231778 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 43 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.40% | 46067 NS | 2026年7月31日 | N-PORT |
| HAPS · Harbor ETF Trust | 0.82% | 46575 NS | 2026年7月31日 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trus... | 0.50% | 3546 SH | 2026年10月2日 | 每日 |
| LABU · Direxion Shares ETF Trust | 0.41% | 67945 NS | 2026年7月31日 | N-PORT |
| FYC · First Trust Exchange-Traded Alpha... | 0.32% | 139210 NS | 2026年7月31日 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.22% | 17481 SH | 2026年10月2日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.15% | 119054 SH | 2026年10月2日 | 每日 |
| IBB · iShares Trust | 0.14% | 425302 SH | 2026年9月11日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.13% | 48730 SH | 2026年8月19日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.13% | 4219 SH | 2026年10月2日 | 每日 |
| PWS · Pacer Funds Trust | 0.12% | 928 NS | 2026年7月31日 | N-PORT |
| FYX · First Trust Exchange-Traded Alpha... | 0.10% | 47013 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.07% | 340226 SH | 2026年8月19日 | 每日 |
| FAD · First Trust Exchange-Traded Alpha... | 0.07% | 12610 NS | 2026年7月31日 | N-PORT |
| IWM · iShares Trust | 0.07% | 1511496 SH | 2026年9月11日 | 每日 |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.07% | 15124 NS | 2026年7月31日 | N-PORT |
| ESML · iShares Trust | 0.06% | 50007 SH | 2026年9月11日 | 每日 |
| VBK · VANGUARD INDEX FUNDS | 0.06% | 788655 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.06% | 28271 NS | 2026年7月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.04% | 192387 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.04% | 10228 SH | 2026年9月11日 | 每日 |
| DXUV · Dimensional ETF Trust | 0.03% | 5807 NS | 2026年7月31日 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.03% | 1364364 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.03% | 167169 SH | 2026年8月19日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 26897 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.02% | 683802 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.02% | 3364 SH | 2026年9月11日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.01% | 3639 SH | 2026年8月19日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.01% | 148210 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 9209 NS | 2026年7月31日 | N-PORT |
| IWO · iShares Trust | 0.01% | 31737 SH | 2026年9月11日 | 每日 |
| TILT · FlexShares Trust | 0.01% | 4553 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 17627 NS | 2026年7月31日 | N-PORT |
| IWV · iShares Trust | 0.00% | 16716 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.00% | 76792 SH | 2026年9月11日 | 每日 |
| DFUS · Dimensional ETF Trust | 0.00% | 17217 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1890189 SH | 2026年8月19日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.00% | 46943 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 4834 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.00% | 13097 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | · | 521555 SH | 2026年9月11日 | 每日 |
| ISCB · iShares Trust | · | 2551 SH | 2026年9月11日 | 每日 |
| ISCV · iShares Trust | · | 5020 SH | 2026年9月11日 | 每日 |
AGIO 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 16 位分析师
买入
中位数目标
$44.50
+39.9%
5 31.2%
强烈买入
7 43.8%
买入
4 25.0%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
8 位分析师 · 2026-10-04平均目标 $46.25 +45.4%
← 低于所有目标
当前价格 $31.80
最低$32.00
平均值$46.25
最高$73.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| GENB | · | · | · | · | · | · |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 30, 2026 申报